[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614830":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":25,"responsibleParty":35,"collaborators":25,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":25,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":25,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":25,"overallStatus":58,"whyStopped":25,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":25},{"fullName":5,"class":6},"Mansoura University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Phenolic complex k110-42","ACTIVE_COMPARATOR","900mg\u002Fkg oral once sachet for 6 month",[13],"Drug: Phenolic complex k110-42",{"label":15,"type":16,"description":17,"interventionNames":18},"Neumentix","PLACEBO_COMPARATOR","Sachet once for 6 month",[19],"Drug: Neumentix",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","900 mg\u002Fkg once oral in form of sachet for 6 month",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"0 mg\u002Fkg once sachet oral for 6 month",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Haidi Sameh Elassal, Master","CONTACT","0201061044831","Haydi.elassal@yahoo.com",{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Haidi Sameh Ahmed Elassal","Resident","100614830","phase-3-phenolic-complex-k110-42-therapy-on-cognitive-functions-in-down-children-100614830",false,"NCT07284693","Phenolic Complex k110-42 Therapy on Cognitive Functions in Down Children","Clinical Study Evaluating the Efficacy of Phenolic Complex k110-42 Therapy on Cognitive Functions of Children With Down Syndrome","Inclusion Criteria:\n\n* Children diagnosed with Down syndrome (Non disjunction Trisomy 21) based on genetic testing .\n* Age between 4-8 years old .\n* Down syndrome children presented with difficulties in attention or focus as reported by parents or based on prior clinical assessments.\n\nExclusion Criteria:\n\n* Parents' refusal.\n* Down syndrome children with other significant developmental or neurological disorders (e.g., autism spectrum disorder, epilepsy).\n* Patients with any chronic illness as liver or renal dysfunction; inflammatory diseases; autoimmune disease; cancer, acute cardiovascular event, eating disorders (anorexia, bulimia) or gastrointestinal disorders.\n* Presence of hypersensitivity to spearmint or any components of Neumentix (Neumentix may increase kidney or liver damage if used in large amounts).\n* Use of stimulant ADHD medication or cognitive-enhancing supplements .\n* IQ test less than 55%.\n* Patients with hypothyroidism.","ALL","4 Years","8 Years",{"count":50,"type":51},108,"ESTIMATED","INTERVENTIONAL",[54],"PHASE3","The goal of this study is to evaluate the efficacy of phenolic complex k110-42 on cognitive function of children with Down syndrome",[57],"Cognitive Functions","NOT_YET_RECRUITING","2025-12-14",{"date":61,"type":62},"2025-12-16","ACTUAL",{"date":64,"type":51},"2026-01",{"date":66,"type":51},"2026-12",{"name":5,"class":6}]